THE COPPER INDEX · FORMULAS UNDER THE LENSSOURCE DATES IN EACH REVIEW
Cucopper indexMORE FORMULAS. CLOSER READING.
Advertising disclosure: CoreAge Rx is our featured commercial partner and appears first. Placement is promotional; it is not a clinical superiority ranking. How we are funded
Clinician-guided compounded care

CoreAge Rx review

CoreAge Rx is the prescription-service choice in this selection. Its first position is commercial; the most important pre-purchase question is the actual Bounce Back prescription.

What stands out

  • Dedicated Bounce Back formula
  • Online clinical assessment

What to weigh

  • Product page says 2%; help catalog says 0.2%. Confirm the dispensed strength.

A medical review is part of the offer

Bounce Back sits in a catalog of compounded skincare treatments. CoreAge Rx describes an online questionnaire, clinician assessment and pharmacy shipment when a prescription is issued. The consultation should establish suitability, not simply approve a shopping preference.[source]

Ask how the prescriber will handle existing skin disease, other active products and a reaction. Customer-service availability alone cannot establish the speed or scope of clinical follow-up.

Resolve the published strength discrepancy

The dedicated product page describes copper peptide 2%, while the help catalog describes Bounce Back as 0.2%. Both were accessible during this edition’s research. We have not silently converted or averaged these values.[source][source]

Request the intended concentration, peptide identity and complete dispensing label. Until the provider reconciles its descriptions, a percentage-based comparison with NIOD or another formula would be misleading.

Separate the starting price from the commitment

The current product page starts at $64.99 per month and advertises delivery without a membership fee. The catalog discusses multi-month purchase terms. Confirm the actual amount due, supplied quantity and cancellation terms for the chosen option.[source]

A product charge should be compared with another product charge; any medical assessment and continuing support should be described separately so the apparent value does not depend on hidden assumptions.

What the commercial position does not establish

We found no head-to-head trial of Bounce Back against the other selections. General copper research cannot validate an undisclosed finished formula, and compounded status is different from FDA approval of a specific drug.[source]

This service may appeal to someone seeking clinician guidance around copper skincare. The individual review preserves the unresolved label question rather than substituting marketing confidence for verification.

How the new serum alternatives change the comparison

The expanded directory adds Biossance and Allies of Skin as clearly labeled serums. Compare their ingredient disclosures with the exact Bounce Back prescription or product information offered by CoreAge Rx. A similar copper-peptide theme does not mean the base, concentration, care model or evidence is the same.

Use the serum comparison to examine bottle economics and study claims. The added options do not change the commercial basis of CoreAge Rx’s first placement or establish a clinical ranking across the formulations.

THE RESEARCH

Sources & further reading

Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.

  1. CoreAge Rx: Bounce BackCurrent page advertises 2% and from $64.99/month · Checked October 8, 2026
  2. CoreAge Rx: help catalogCatalog instead lists 0.2%; discrepancy remains unresolved · Checked October 8, 2026
  3. FDA: compounding questions and answersOfficial source; checked October 8, 2026 · Checked October 8, 2026

Keep reading